USFDA concludes inspection at Alembic Pharma's Bioequivalence Facility

25 Oct 2022 , 09:24 AM

Alembic Pharmaceuticals Limited informed that it has successfully completed the USFDA inspection for its Bioequivalence Facility located at Vadodara.

USFDA has completed the inspection without any observations.

The inspection took place from October 17 to October 21, 2022.

Alembic Pharmaceuticals Ltd. is a worldwide pharmaceutical firm based in Vadodara, India. It is engaged in the production of pharmaceutical goods, pharmaceutical ingredients, and pharmaceutical intermediates. In India, it is also considered as a market leader in the macrolides sector of anti-infective medications.

At around 9.26 AM, Alembic Pharmaceuticals was trading at Rs547.10 down by 0.28% from its previous closing of Rs548.65 on the BSE. The scrip opened at Rs550.85 and touched intraday high and low of Rs557.95 and Rs547.10 respectively.

For feedback and suggestions, write to us at [e-mail]